Given the strong immune response elicited at the tumor site by intravenous dosing of exoASO-STAT6, we assessed whether systemic inflammation was also induced by exoASO treatment by measuring cytokines in the serum of treated animals at the end of the study. Here, STAT6 is linked to neoplasm.